Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says

MT Newswires05-11

Iovance Biotherapeutics' (IOVA) "disciplined" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434860358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-11 01:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2434860358","market":"us","top_or_hot":-1,"title":"Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says","media":"MT Newswires","content":"<div>\n<p>Iovance Biotherapeutics' (IOVA) \"disciplined\" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping ...</p>\n\n<a href=\"https://finance.yahoo.com/news/iovance-biotherapeutics-apos-patient-selection-173544625.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-11 01:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/iovance-biotherapeutics-apos-patient-selection-173544625.html><strong>MT Newswires</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics' (IOVA) \"disciplined\" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping ...</p>\n\n<a href=\"https://finance.yahoo.com/news/iovance-biotherapeutics-apos-patient-selection-173544625.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/iovance-biotherapeutics-apos-patient-selection-173544625.html","article_id":"2434860358","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434860358","pubTimestamp":1715362544,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Iovance Biotherapeutics'  \"disciplined\" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping minimize patient attrition, Truist Securities said in a note Friday.The company reported having enrolled over 100 patients for treatment, which Truist described as solid.\"Based on our analysis, time from enrollment to receiving therapy  is taking longer than what was anticipated, but this is likely to improve as treatment centers and payors become more familiar,\" Truist Securities said, adding it expects more than 60 patients treated would contribute to the company's Q2 revenue.Enrollment to infusion currently takes around three months, but this could be shortened to six to eight weeks as each authorized treatment center gains more experience in handling patients, the note said. Truist said the number of treatment centers is on track to reach about 50 by end of this month and 70 by year-end.Trui","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc.","TFC":"Truist Financial Corp"},"translate_title":"Truist Securities表示，Iovance Biotherapeutics为Amtagvi推出的患者选择将损耗降至最低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9,"TFC":0.9},"content_text":"Iovance Biotherapeutics' (IOVA) \"disciplined\" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping minimize patient attrition, Truist Securities said in a note Friday.\n\n The company reported having enrolled over 100 patients for treatment, which Truist described as solid.\n\n \"Based on our analysis, time from enrollment to receiving therapy (which is the billable, revenue-generating event) is taking longer than what was anticipated, but this is likely to improve as treatment centers and payors become more familiar,\" Truist Securities said, adding it expects more than 60 patients treated would contribute to the company's Q2 revenue. \n\n Enrollment to infusion currently takes around three months, but this could be shortened to six to eight weeks as each authorized treatment center gains more experience in handling patients, the note said. Truist said the number of treatment centers is on track to reach about 50 by end of this month and 70 by year-end.\n\n Truist maintained its buy rating on Iovance Biotherapeutics with a price target of $26.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434860358"}